Skip to content

Lorraine Registry of Multiple Sclerosis

Lorraine Registry of Multiple Sclerosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02883335
Acronym
RelSEP
Enrollment
6000
Registered
2016-08-30
Start date
2003-05-31
Completion date
2030-01-31
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The RelSEP aims to register exhaustively every new case of multiple sclerosis (MS) occuring in Lorraine a French region, and follow up on them for an indefinite duration, registering disease evolution and intercurrent events.

Detailed description

As every patient registry in France, the RelSEP is periodically (every four years) evaluated by an independent committee. The RelSEP interrogate multiple sources to insure its exhaustiveness : * every neurologists of Lorraine * MS patient network in Lorraine * health insurance data * PMSI (administrative French national database for hospitals) * biological and imagery services in Lorraine Procedures (automatic and manual) are used to eliminate duplicates Once a patient has been identified its medical file are checked by investigators in order to retrieve the relevant information. New MS cases are confirmed by neurologists. Automatics (implemented in EDMUS software)and manual checks are implemented in the registry database, looking for inconsistencies. The following data are registered : * Name, birthname * Sex * Date of birth * Location (town) * Birth location (town) * Profession * Number of siblings * Marital status * Number of children * Date of onset * Date and nature of clinical manifestations * MRI reports * CSF analysis reports * Event-related potential reports * Impairment and disability evolution * Treatments (start and change of drug treatment) * Drugs related events * Cause of treatment discontinuation * Disease progression Every case has a follow up at least every two years. The quality of data is evaluated by periodically auditing cases at random from our database. An annual report on the main data (incidence and prevalence) of MS in Lorraine is produced. Data are also used for observational studies on prognostic factors.

Interventions

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
University of Lorraine
CollaboratorOTHER
Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Having a confirmed multiple sclerosis diagnosis * Living in Lorraine (French region)

Exclusion criteria

* Refusal to be registered

Design outcomes

Primary

MeasureTime frame
case occurence of multiple sclerosisone year

Secondary

MeasureTime frame
EDSS score30 years

Countries

France

Contacts

Primary ContactFrancis Guillemin, MD, PHD
francis.guillemin@chru-nancy.fr
Backup ContactJonathan Epstein, MD, MSc
j.epstein@chru-nancy.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026